De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Hims & Hers Health Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Hims & Hers Health is de winst gegroeid met een gemiddeld jaarlijks percentage van 15.5%, terwijl de Healthcare industrie de winst jaarlijks groeide met 6.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 52.4% per jaar. Het rendement op eigen vermogen van Hims & Hers Health is 5%, en het heeft een nettomarge van 1.7%.
Belangrijke informatie
15.5%
Groei van de winst
51.6%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.5% |
| Inkomstengroei | 52.4% |
| Rendement op eigen vermogen | 5.0% |
| Nettomarge | 1.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Opbrengsten en kosten
Hoe Hims & Hers Health geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,067 | 18 | 802 | 60 |
| 31 Mar 24 | 959 | -2 | 743 | 53 |
| 31 Dec 23 | 872 | -24 | 693 | 48 |
| 30 Sep 23 | 793 | -36 | 639 | 43 |
| 30 Jun 23 | 711 | -47 | 581 | 39 |
| 31 Mar 23 | 616 | -59 | 514 | 34 |
| 31 Dec 22 | 527 | -66 | 446 | 29 |
| 30 Sep 22 | 444 | -86 | 381 | 26 |
| 30 Jun 22 | 374 | -83 | 324 | 35 |
| 31 Mar 22 | 321 | -73 | 281 | 28 |
| 31 Dec 21 | 272 | -108 | 289 | 22 |
| 30 Sep 21 | 229 | -82 | 250 | 17 |
| 30 Jun 21 | 196 | -72 | 217 | 0 |
| 31 Mar 21 | 171 | -63 | 186 | 0 |
| 31 Dec 20 | 149 | -18 | 113 | 11 |
| 30 Sep 20 | 132 | -25 | 117 | 0 |
| 30 Jun 20 | 112 | -38 | 114 | 0 |
| 31 Mar 20 | 95 | -58 | 117 | 0 |
| 31 Dec 19 | 83 | -72 | 119 | 0 |
| 31 Dec 18 | 27 | -75 | 84 | 0 |
Kwaliteitswinsten: HIMS heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: HIMS is in het verleden winstgevend geweest.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: HIMS is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 15.5% per jaar laten groeien.
Versnelling van de groei: HIMS is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.
Winst versus industrie: HIMS is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare -sector ( 8% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 5% ) van HIMS wordt als laag beschouwd.